This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
by Zacks Equity Research
Novo Nordisk stock up as it teams up with OpenAI to deploy AI across drug discovery and operations, aiming to speed therapies, boost efficiency and counter rising competition.
NVONegative Net Change LLYPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
CGON Stock Up 60.8% in Six Months: Here's What You Need to Know
by Zacks Equity Research
CG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence.
ANIPPositive Net Change INDVPositive Net Change CGONPositive Net Change
biotechs
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
by Zacks Equity Research
Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
REGNPositive Net Change SNYNegative Net Change TLXPositive Net Change
biotechnology biotechs medical pharmaceuticals
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
by Zacks Equity Research
Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.
ANIPPositive Net Change KYMRPositive Net Change INDVPositive Net Change
biotechs
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
by Zacks Equity Research
Revolution Medicines jumps 41% as phase III data show daraxonrasib boosts survival in metastatic PDAC, paving the way for global regulatory filings.
ANIPPositive Net Change RVMDPositive Net Change INDVPositive Net Change
biotechs
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
by Zacks Equity Research
Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL treatment.
AGENPositive Net Change ALLONegative Net Change INDVPositive Net Change
biotechs
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
by Ahan Chakraborty
Novo Nordisk faces rising pressure as LLY launches Foundayo, a rival obesity pill, challenging Wegovy despite data suggesting NVO's edge in efficacy.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Apr 14, 2026
by Zacks Equity Research
Companies In The News Are: SNDK, ALLO, CAG, ORCL.
SNDKPositive Net Change ORCLNegative Net Change CAGNegative Net Change ALLONegative Net Change
artificial-intelligence biotechs computers consumer-staples
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
by Zacks Equity Research
REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.
BMYPositive Net Change ADMANegative Net Change REPLNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk plunges 36% in three months as a weak 2026 outlook, rising competition and pricing pressure cloud near-term growth despite long-term pipeline promise.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals